Enterprise Value
10.2M
Cash
36.57M
Avg Qtr Burn
-9.404M
Short % of Float
1.40%
Insider Ownership
0.31%
Institutional Own.
17.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CRB-701 (Nectin-4 ADC) Details Solid tumor/s, Urothelial cancer | Phase 1 Initiation | |
CRB-601 (anti-αvβ8) Details Solid tumor/s | IND Submission | |
Lenabasum Details Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease | Failed Discontinued | |
Lenabasum Details Cystic fibrosis | Failed Discontinued | |
Lenabasum Details Systemic sclerosis | Failed Discontinued | |
Lenabasum (JBT-101) Details Autoimmune disease | Failed Discontinued |